CEMIP and pancreatic neoplasm: In early-stage pancreatic cancer, combined use of CEMIP and CA 19-9 showed higher AUROC than CA 19-9 alone (0.95 vs. 0.85, P = 0.0004) (Supplementary Figure 2).